title: Hemostasis in aortic and cardiothoracic surgery.
abstract: Hemostasis abnormalities in cardiovascular and aortic surgery remain a major source of morbidity and mortality in patients undergoing such complex procedures. The need for frequent transfusions of red cell and other blood products increases risks and costs to patients and institutions providing patient care. Specifically in cardiovascular and aortic surgery, the nature of the surgery is, at best, semi-elective, and careful preparation to preserve the hemostatic mechanisms of the body is essential. Contact of blood with the extracorporeal circuit induces a hemorrhagic diathesis through a variety of different mechanisms. Dilution of the patient's blood volume by the extracorporeal circuit prime causes depletion of platelets and coagulation factor levels. Aorto intimal disease initiates fibrinolysis by the release of tissue plasminogen activator. Due to the numerous etiologies of bleeding, a combination of blood conservation strategies is suggested. The ideal combination of interventions has yet to be determined and is currently dependent on patient variables, physician and institutional practices, and economic pressures.
authors.affiliation: Mount Sinai Medical Center, New York, New York, USA.
authors.forename: L
authors.initials: L
authors.lastname: Shore-Lesserson
authors.forename: D L
authors.initials: DL
authors.lastname: Reich
authors.forename: G
authors.initials: G
authors.lastname: Silvay
authors.forename: R B
authors.initials: RB
authors.lastname: Griepp
mesh_terms: D015119:Aminocaproic Acid / Q000627:therapeutic use; D000933:Antifibrinolytic Agents / Q000627:therapeutic use; D007611:Aprotinin / Q000627:therapeutic use; D001778:Blood Coagulation Disorders / Q000209:etiology; D006488:Hemostasis, Surgical / Q000379:methods*; D006490:Hemostatics / Q000627:therapeutic use*; D006801:Humans
chemical_list: D000933:Antifibrinolytic Agents; D006490:Hemostatics; D007611:Aprotinin; D015119:Aminocaproic Acid